APUS Market Analysis
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-35.100.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$2.4MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.02
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- —
Last earnings
Aug 14, 2026 · Reported $-11.77
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Apimeds Pharmaceuticals US, Inc.
Company profileApimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company in the United States. The company is headquartered in Hopewell, New Jersey.
Classification
- Sector
- Healthcare
- Exchange
- NYSE MKT
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 100 MATAWAN RD, MATAWAN, NJ
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$2.4M
Shares outstanding$1.5M
52W high$40.31
52W low$1.51
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent